Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 16 studies | 39% ± 14% | |
lung | 11 studies | 32% ± 16% | |
uterus | 6 studies | 33% ± 9% | |
intestine | 5 studies | 37% ± 10% | |
skin | 4 studies | 55% ± 24% | |
lymph node | 4 studies | 46% ± 12% | |
breast | 4 studies | 24% ± 7% | |
kidney | 3 studies | 38% ± 10% | |
bone marrow | 3 studies | 35% ± 14% | |
prostate | 3 studies | 20% ± 4% | |
liver | 3 studies | 43% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
intestine | 100% | 4494.99 | 964 / 966 | 98% | 39.22 | 519 / 527 |
lung | 100% | 11140.45 | 578 / 578 | 98% | 54.71 | 1133 / 1155 |
esophagus | 94% | 2821.52 | 1362 / 1445 | 99% | 88.57 | 181 / 183 |
uterus | 99% | 2985.82 | 169 / 170 | 92% | 41.65 | 420 / 459 |
breast | 99% | 4825.41 | 456 / 459 | 91% | 28.89 | 1014 / 1118 |
ovary | 100% | 13132.45 | 180 / 180 | 90% | 28.04 | 385 / 430 |
bladder | 100% | 3328.90 | 21 / 21 | 88% | 37.94 | 446 / 504 |
stomach | 89% | 2598.60 | 321 / 359 | 99% | 49.95 | 283 / 286 |
skin | 99% | 6703.69 | 1793 / 1809 | 86% | 32.40 | 405 / 472 |
prostate | 98% | 3473.82 | 240 / 245 | 85% | 23.74 | 426 / 502 |
pancreas | 72% | 1512.05 | 237 / 328 | 97% | 42.42 | 172 / 178 |
kidney | 79% | 2571.60 | 70 / 89 | 88% | 37.42 | 795 / 901 |
thymus | 90% | 2417.23 | 585 / 653 | 74% | 19.96 | 448 / 605 |
adrenal gland | 95% | 2858.90 | 246 / 258 | 67% | 23.47 | 153 / 230 |
liver | 71% | 1718.28 | 161 / 226 | 80% | 23.70 | 324 / 406 |
adipose | 100% | 9040.80 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 99.25 | 29 / 29 |
spleen | 100% | 7147.00 | 241 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 96% | 12516.38 | 896 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 81.07 | 43 / 45 |
blood vessel | 80% | 2245.52 | 1073 / 1335 | 0% | 0 | 0 / 0 |
heart | 54% | 1992.86 | 468 / 861 | 0% | 0 | 0 / 0 |
brain | 6% | 132.29 | 170 / 2642 | 43% | 8.02 | 306 / 705 |
muscle | 30% | 483.46 | 237 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 14% | 1.84 | 11 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_2000349 | Biological process | negative regulation of CD40 signaling pathway |
GO_0071108 | Biological process | protein K48-linked deubiquitination |
GO_2000352 | Biological process | negative regulation of endothelial cell apoptotic process |
GO_2000347 | Biological process | positive regulation of hepatocyte proliferation |
GO_0006954 | Biological process | inflammatory response |
GO_0070429 | Biological process | negative regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway |
GO_0070433 | Biological process | negative regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway |
GO_0032703 | Biological process | negative regulation of interleukin-2 production |
GO_0034136 | Biological process | negative regulation of toll-like receptor 2 signaling pathway |
GO_0035523 | Biological process | protein K29-linked deubiquitination |
GO_0061043 | Biological process | regulation of vascular wound healing |
GO_0032715 | Biological process | negative regulation of interleukin-6 production |
GO_0045779 | Biological process | negative regulation of bone resorption |
GO_0001922 | Biological process | B-1 B cell homeostasis |
GO_0002634 | Biological process | regulation of germinal center formation |
GO_0032495 | Biological process | response to muramyl dipeptide |
GO_0002237 | Biological process | response to molecule of bacterial origin |
GO_1990168 | Biological process | protein K33-linked deubiquitination |
GO_0002677 | Biological process | negative regulation of chronic inflammatory response |
GO_0034144 | Biological process | negative regulation of toll-like receptor 4 signaling pathway |
GO_0071947 | Biological process | protein deubiquitination involved in ubiquitin-dependent protein catabolic process |
GO_0007010 | Biological process | cytoskeleton organization |
GO_0010803 | Biological process | regulation of tumor necrosis factor-mediated signaling pathway |
GO_0032691 | Biological process | negative regulation of interleukin-1 beta production |
GO_0032088 | Biological process | negative regulation of NF-kappaB transcription factor activity |
GO_0070301 | Biological process | cellular response to hydrogen peroxide |
GO_0045732 | Biological process | positive regulation of protein catabolic process |
GO_0045824 | Biological process | negative regulation of innate immune response |
GO_0070936 | Biological process | protein K48-linked ubiquitination |
GO_0070536 | Biological process | protein K63-linked deubiquitination |
GO_0050728 | Biological process | negative regulation of inflammatory response |
GO_0030177 | Biological process | positive regulation of Wnt signaling pathway |
GO_0031397 | Biological process | negative regulation of protein ubiquitination |
GO_0090291 | Biological process | negative regulation of osteoclast proliferation |
GO_0006508 | Biological process | proteolysis |
GO_0034140 | Biological process | negative regulation of toll-like receptor 3 signaling pathway |
GO_0048662 | Biological process | negative regulation of smooth muscle cell proliferation |
GO_0016579 | Biological process | protein deubiquitination |
GO_0071222 | Biological process | cellular response to lipopolysaccharide |
GO_0006915 | Biological process | apoptotic process |
GO_1902042 | Biological process | negative regulation of extrinsic apoptotic signaling pathway via death domain receptors |
GO_0072666 | Biological process | establishment of protein localization to vacuole |
GO_0034148 | Biological process | negative regulation of toll-like receptor 5 signaling pathway |
GO_0072573 | Biological process | tolerance induction to lipopolysaccharide |
GO_0032720 | Biological process | negative regulation of tumor necrosis factor production |
GO_0050691 | Biological process | regulation of defense response to virus by host |
GO_0035871 | Biological process | protein K11-linked deubiquitination |
GO_0050869 | Biological process | negative regulation of B cell activation |
GO_0016477 | Biological process | cell migration |
GO_0043124 | Biological process | negative regulation of canonical NF-kappaB signal transduction |
GO_0035872 | Biological process | nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway |
GO_0005764 | Cellular component | lysosome |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0070530 | Molecular function | K63-linked polyubiquitin modification-dependent protein binding |
GO_0004843 | Molecular function | cysteine-type deubiquitinase activity |
GO_0019900 | Molecular function | kinase binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0002020 | Molecular function | protease binding |
GO_0008270 | Molecular function | zinc ion binding |
GO_0061578 | Molecular function | K63-linked deubiquitinase activity |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0005515 | Molecular function | protein binding |
GO_0043130 | Molecular function | ubiquitin binding |
Gene name | TNFAIP3 |
Protein name | Truncated tumor necrosis factor alpha-induced protein 3 ubiquitinyl hydrolase 1 (EC 3.4.19.12) Tumor necrosis factor alpha-induced protein 3 Tumor necrosis factor alpha-induced protein 3 (TNF alpha-induced protein 3) (EC 2.3.2.-) (EC 3.4.19.12) (OTU domain-containing protein 7C) (Putative DNA-binding protein A20) (Zinc finger protein A20) [Cleaved into: A20p50; A20p37] TNF alpha induced protein 3 TNFAIP3 (A20) |
Synonyms | OTUD7C |
Description | FUNCTION: Ubiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities. Involved in immune and inflammatory responses signaled by cytokines, such as TNF-alpha and IL-1 beta, or pathogens via Toll-like receptors (TLRs) through terminating NF-kappa-B activity. Essential component of a ubiquitin-editing protein complex, comprising also RNF11, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signaling pathways. In cooperation with TAX1BP1 promotes disassembly of E2-E3 ubiquitin protein ligase complexes in IL-1R and TNFR-1 pathways; affected are at least E3 ligases TRAF6, TRAF2 and BIRC2, and E2 ubiquitin-conjugating enzymes UBE2N and UBE2D3. In cooperation with TAX1BP1 promotes ubiquitination of UBE2N and proteasomal degradation of UBE2N and UBE2D3. Upon TNF stimulation, deubiquitinates 'Lys-63'-polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NF-kappa-B. Deubiquitinates TRAF6 probably acting on 'Lys-63'-linked polyubiquitin. Upon T-cell receptor (TCR)-mediated T-cell activation, deubiquitinates 'Lys-63'-polyubiquitin chains on MALT1 thereby mediating disassociation of the CBM (CARD11:BCL10:MALT1) and IKK complexes and preventing sustained IKK activation. Deubiquitinates NEMO/IKBKG; the function is facilitated by TNIP1 and leads to inhibition of NF-kappa-B activation. Upon stimulation by bacterial peptidoglycans, probably deubiquitinates RIPK2. Can also inhibit I-kappa-B-kinase (IKK) through a non-catalytic mechanism which involves polyubiquitin; polyubiquitin promotes association with IKBKG and prevents IKK MAP3K7-mediated phosphorylation. Targets TRAF2 for lysosomal degradation. In vitro able to deubiquitinate 'Lys-11'-, 'Lys-48'- and 'Lys-63' polyubiquitin chains. Inhibitor of programmed cell death. Has a role in the function of the lymphoid system. Required for LPS-induced production of pro-inflammatory cytokines and IFN beta in LPS-tolerized macrophages. . |
Accessions | D3TTZ6 D3TTZ4 ENST00000711061.1 D3TTZ5 Q5VXQ9 ENST00000421450.1 D3TTZ3 D3TTZ2 ENST00000420009.5 D3TTZ8 P21580 ENST00000420009.6 Q5VXR0 F8K9X7 ENST00000433680.1 D3TTZ7 ENST00000237289.8 A0AA34QW12 D3TTY9 D3TTY6 D3TTY8 D3TTY5 D3TTZ0 ENST00000612899.5 D3TTY7 D3TTZ1 ENST00000433680.2 ENST00000421450.2 D3TTY4 Q5VXQ8 |